CA2638176C - Oligonucleotide et son utilisation - Google Patents

Oligonucleotide et son utilisation Download PDF

Info

Publication number
CA2638176C
CA2638176C CA2638176A CA2638176A CA2638176C CA 2638176 C CA2638176 C CA 2638176C CA 2638176 A CA2638176 A CA 2638176A CA 2638176 A CA2638176 A CA 2638176A CA 2638176 C CA2638176 C CA 2638176C
Authority
CA
Canada
Prior art keywords
immune
oligonucleotide
mediated
mediated disorder
tlr9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2638176A
Other languages
English (en)
Other versions
CA2638176A1 (fr
Inventor
Liying Wang
Dali Hu
Ran SUN
Yongli Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Priority to CA2638176A priority Critical patent/CA2638176C/fr
Publication of CA2638176A1 publication Critical patent/CA2638176A1/fr
Application granted granted Critical
Publication of CA2638176C publication Critical patent/CA2638176C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oligonucléotide présentant la séquence de nucléotides suivante : 5'-cctcctcctcctcctcctcctcct- 3'. Linvention empêche la prolifération de la cellule mononuclée de sang périphérique (PBMC) humaine activée par lagoniste TLR9 et la production dinterféron provenant de la PBMC humane induite par lagoniste TLR9, le HSV-1, le virus de la grippe et le sérum provenant des patients atteints de lupus érythémateux disséminé (LES), en plus de sauver les souris du choc létal attribuable à la cytokine. Cet oligonucléotide peut être utilisé comme remède pour le traitement du LES, de la sepsie, des syndromes de dysfonction des organes multiples et dautres troubles dorigine immunologique.
CA2638176A 2008-08-01 2008-08-01 Oligonucleotide et son utilisation Expired - Fee Related CA2638176C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2638176A CA2638176C (fr) 2008-08-01 2008-08-01 Oligonucleotide et son utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2638176A CA2638176C (fr) 2008-08-01 2008-08-01 Oligonucleotide et son utilisation

Publications (2)

Publication Number Publication Date
CA2638176A1 CA2638176A1 (fr) 2010-02-01
CA2638176C true CA2638176C (fr) 2016-09-13

Family

ID=41693061

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2638176A Expired - Fee Related CA2638176C (fr) 2008-08-01 2008-08-01 Oligonucleotide et son utilisation

Country Status (1)

Country Link
CA (1) CA2638176C (fr)

Also Published As

Publication number Publication date
CA2638176A1 (fr) 2010-02-01

Similar Documents

Publication Publication Date Title
US10190122B2 (en) Inhibitory oligonucleotide and use thereof
US8030289B2 (en) Oligonucleotide and use thereof
EP1511845B1 (fr) Oligonucleotides immunostimulateurs et leur utilisation
US20050239733A1 (en) Sequence requirements for inhibitory oligonucleotides
CN101541965A (zh) Tlr配体与抗病毒剂的组合物
US10806749B2 (en) TLR inhibitory oligonucleotides and their use
EP2154144B1 (fr) Oligonucléotides et leur utilisation
US9868955B2 (en) Human toll-like receptor inhibitors and methods of use thereof
WO2014052931A1 (fr) Inhibiteurs du récepteur humain de type toll et procédés d'utilisation de ceux-ci
CA2897125A1 (fr) Oligonucleotides inhibiteurs et leur utilisation en therapie
CN115413298A (zh) 具有免疫调节功能的CpG ODN及其应用
JP6307190B2 (ja) 阻害性オリゴヌクレオチド及びその使用
CA2638176C (fr) Oligonucleotide et son utilisation
CN101643496B (zh) 一种具有免疫抑制功能的寡核苷酸
JP5415724B2 (ja) 一種のオリゴヌクレオチド及びその応用
JP2014073126A (ja) 一種のオリゴヌクレオチド及びその応用
CA2487904A1 (fr) Oligonucleotides immunostimulateurs et leur utilisation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130117

MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831